The platform is a collaborative video solution that enables doctors and medical staff to deliver seamless health care experiences to patients through this digital interface
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Flipkart also announced its foray into the healthcare sector through the launch of Flipkart Health+
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Subscribe To Our Newsletter & Stay Updated
